gliclazide has been researched along with Diabetic Retinopathy in 19 studies
Gliclazide: An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.
Diabetic Retinopathy: Disease of the RETINA as a complication of DIABETES MELLITUS. It is characterized by the progressive microvascular complications, such as ANEURYSM, interretinal EDEMA, and intraocular PATHOLOGIC NEOVASCULARIZATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gliclazide has been reported to possess the properties of preventing the progression of diabetic retinopathy and of controlling blood glucose levels." | 9.06 | Long-term comparison of oral hypoglycemic agents in diabetic retinopathy. Gliclazide vs. other sulfonylureas. ( Akanuma, Y; Aoki, S; Fukuda, M; Kanazawa, Y; Kasuga, M; Kosaka, K, 1988) |
| "Gliclazide is a 'second generation' oral hypoglycaemic agent." | 7.75 | Gliclazide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in diabetes mellitus. ( Avery, GS; Brogden, RN; Heel, RC; Holmes, B; Speight, TM, 1984) |
| "To investigate the dynamics of the intracellular Ca2+ concentration ([Ca2+]i) during retinal ischemia in rats with streptozotocin (STZ)-induced diabetes and the effect of gliclazide, a sulfonylurea with a potent free-radical scavenging activity on ischemia-induced [Ca2+]i dynamics." | 7.73 | Gliclazide attenuates the intracellular Ca2+ changes induced in vitro by ischemia in the retinal slices of rats with streptozotocin-induced diabetes. ( Harata, N; Kinukawa, J; Shimura, M; Tamai, M, 2005) |
| "This suggests that gliclazide could directly improve abnormalities in the retinal microcirculation independent of blood glucose control and possibly have selective therapeutic benefits in preventing early, critical events in diabetic retinopathy compared with other sulphonylurea drugs." | 7.71 | Effective and selective prevention of retinal leukostasis in streptozotocin-induced diabetic rats using gliclazide. ( Inoda, S; Itou, Y; Kakehashi, A; Kanazawa, Y; Kawakami, M; Kinoshita, N; Kuroki, M; Yasu, T, 2002) |
| "The effects of long-term treatment with gliclazide on diabetic retinopathy and platelet adhesion were investigated." | 7.66 | Preventive and therapeutic effects of gliclazide on diabetic retinopathy: comparison with glibenclamide treatment. ( Abe, M; Ikeda, Y; Minami, N, 1983) |
| "Diabetic retinopathy is the most common cause of human blindness between the ages of 30 and 67 in the industrialized world." | 6.67 | Diabetic retinopathy in non-insulin-dependent diabetes mellitus patients: the role of gliclazide. ( Akanuma, Y; Aoki, S; Fukuda, M; Kanazawa, Y; Kasuga, M; Kosaka, K, 1991) |
| "The effects of gliclazide on blood sugar levels and the micro-vascular system have been specified by the latest international studies of this antidiabetic agent presented at the 11th World Congress on Diabetes Mellitus." | 6.15 | [Hypoglycemic and microvascular properties of gliclazide: a review of the latest international studies]. ( Lesobre, B, 1983) |
| "Gliclazide has been reported to possess the properties of preventing the progression of diabetic retinopathy and of controlling blood glucose levels." | 5.06 | Long-term comparison of oral hypoglycemic agents in diabetic retinopathy. Gliclazide vs. other sulfonylureas. ( Akanuma, Y; Aoki, S; Fukuda, M; Kanazawa, Y; Kasuga, M; Kosaka, K, 1988) |
| "Gliclazide has been reported to decrease platelet function and to inhibit the progression of diabetic retinopathy in addition to having a hypoglycemic effect." | 5.05 | Comparison of gliclazide and glibenclamide treatment in non-insulin-dependent diabetes. ( Baba, S; Fukui, I; Goto, Y; Maezawa, H; Nakagawa, S; Sakamoto, N; Takebe, K; Takeda, R, 1983) |
| "Gliclazide is a 'second generation' oral hypoglycaemic agent." | 3.75 | Gliclazide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in diabetes mellitus. ( Avery, GS; Brogden, RN; Heel, RC; Holmes, B; Speight, TM, 1984) |
| "To investigate the dynamics of the intracellular Ca2+ concentration ([Ca2+]i) during retinal ischemia in rats with streptozotocin (STZ)-induced diabetes and the effect of gliclazide, a sulfonylurea with a potent free-radical scavenging activity on ischemia-induced [Ca2+]i dynamics." | 3.73 | Gliclazide attenuates the intracellular Ca2+ changes induced in vitro by ischemia in the retinal slices of rats with streptozotocin-induced diabetes. ( Harata, N; Kinukawa, J; Shimura, M; Tamai, M, 2005) |
| "This suggests that gliclazide could directly improve abnormalities in the retinal microcirculation independent of blood glucose control and possibly have selective therapeutic benefits in preventing early, critical events in diabetic retinopathy compared with other sulphonylurea drugs." | 3.71 | Effective and selective prevention of retinal leukostasis in streptozotocin-induced diabetic rats using gliclazide. ( Inoda, S; Itou, Y; Kakehashi, A; Kanazawa, Y; Kawakami, M; Kinoshita, N; Kuroki, M; Yasu, T, 2002) |
| "The effects of long-term treatment with gliclazide on diabetic retinopathy and platelet adhesion were investigated." | 3.66 | Preventive and therapeutic effects of gliclazide on diabetic retinopathy: comparison with glibenclamide treatment. ( Abe, M; Ikeda, Y; Minami, N, 1983) |
| "In patients with type 2 diabetes, moderate alcohol use, particularly wine consumption, is associated with reduced risks of cardiovascular events and all-cause mortality." | 2.79 | The relationship between alcohol consumption and vascular complications and mortality in individuals with type 2 diabetes. ( Blomster, JI; Chalmers, J; Chow, CK; Harrap, S; Hillis, GS; Li, Q; Mancia, G; Neal, B; Patel, A; Poulter, N; Williams, B; Woodward, M; Zoungas, S, 2014) |
| "Diabetic retinopathy is the most common cause of human blindness between the ages of 30 and 67 in the industrialized world." | 2.67 | Diabetic retinopathy in non-insulin-dependent diabetes mellitus patients: the role of gliclazide. ( Akanuma, Y; Aoki, S; Fukuda, M; Kanazawa, Y; Kasuga, M; Kosaka, K, 1991) |
| "Gliclazide is a second generation sulphonylurea oral hypoglycaemic agent used in the treatment of non-insulin-dependent diabetes mellitus (NIDDM)." | 2.38 | Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus. ( Brogden, RN; Palmer, KJ, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (52.63) | 18.7374 |
| 1990's | 4 (21.05) | 18.2507 |
| 2000's | 3 (15.79) | 29.6817 |
| 2010's | 1 (5.26) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Saberi, M | 1 |
| Ramazani, Z | 1 |
| Rashidi, H | 1 |
| Saberi, A | 1 |
| Blomster, JI | 1 |
| Zoungas, S | 1 |
| Chalmers, J | 1 |
| Li, Q | 1 |
| Chow, CK | 1 |
| Woodward, M | 1 |
| Mancia, G | 1 |
| Poulter, N | 1 |
| Williams, B | 1 |
| Harrap, S | 1 |
| Neal, B | 1 |
| Patel, A | 1 |
| Hillis, GS | 1 |
| Kinukawa, J | 1 |
| Shimura, M | 1 |
| Harata, N | 1 |
| Tamai, M | 1 |
| Li, L | 1 |
| Renier, G | 1 |
| Chan, TK | 1 |
| Chan, V | 1 |
| Teng, CS | 1 |
| Yeung, RT | 1 |
| Lesobre, B | 3 |
| Holmes, B | 1 |
| Heel, RC | 1 |
| Brogden, RN | 2 |
| Speight, TM | 1 |
| Avery, GS | 1 |
| Minami, N | 1 |
| Ikeda, Y | 1 |
| Abe, M | 1 |
| Baba, S | 1 |
| Nakagawa, S | 1 |
| Takebe, K | 1 |
| Goto, Y | 1 |
| Maezawa, H | 1 |
| Takeda, R | 1 |
| Sakamoto, N | 1 |
| Fukui, I | 1 |
| Kumar, S | 1 |
| Keswani, P | 1 |
| Bose, BS | 1 |
| Agrawal, JK | 1 |
| Palmer, KJ | 1 |
| Cathelineau, G | 1 |
| de Champvallins, M | 1 |
| Bouallouche, A | 1 |
| Kinoshita, N | 1 |
| Kakehashi, A | 1 |
| Inoda, S | 1 |
| Itou, Y | 1 |
| Kuroki, M | 1 |
| Yasu, T | 1 |
| Kawakami, M | 1 |
| Kanazawa, Y | 3 |
| Charbonnel, B | 1 |
| Regnault, F | 1 |
| Kojima, K | 1 |
| Harada, T | 1 |
| Suzuki, M | 1 |
| Awaya, S | 1 |
| Ichikawa, H | 1 |
| Akanuma, Y | 2 |
| Kosaka, K | 2 |
| Kasuga, M | 2 |
| Fukuda, M | 2 |
| Aoki, S | 2 |
4 reviews available for gliclazide and Diabetic Retinopathy
| Article | Year |
|---|---|
[Hypoglycemic and microvascular properties of gliclazide: a review of the latest international studies].
Topics: Aged; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus; Diabetic Retinopathy; Female; Glic | 1983 |
[Diabetic retinopathy. Effects of gliclazide].
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Gliclazide; Humans; Sulfo | 1983 |
Gliclazide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in diabetes mellitus.
Topics: Absorption; Animals; Blood Glucose; Blood Platelets; Clinical Trials as Topic; Diabetes Mellitus; Di | 1984 |
Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Diabetic Retinopathy; Drug | 1993 |
11 trials available for gliclazide and Diabetic Retinopathy
| Article | Year |
|---|---|
The relationship between alcohol consumption and vascular complications and mortality in individuals with type 2 diabetes.
Topics: Aged; Alcohol Drinking; Antihypertensive Agents; Coronary Disease; Diabetes Mellitus, Type 2; Diabet | 2014 |
[Effects of gliclazide and glibenclamide on platelet function, fibrinolysis and metabolic control in diabetic patients with retinopathy (author's transl)].
Topics: Blood Glucose; Diabetic Retinopathy; Fibrinolysis; Gliclazide; Glyburide; Glycated Hemoglobin; Human | 1982 |
[Hypoglycemic and microvascular properties of gliclazide: a review of the latest international studies].
Topics: Aged; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus; Diabetic Retinopathy; Female; Glic | 1983 |
[Diabetic retinopathy. Effects of gliclazide].
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Gliclazide; Humans; Sulfo | 1983 |
Gliclazide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in diabetes mellitus.
Topics: Absorption; Animals; Blood Glucose; Blood Platelets; Clinical Trials as Topic; Diabetes Mellitus; Di | 1984 |
Comparison of gliclazide and glibenclamide treatment in non-insulin-dependent diabetes.
Topics: Adult; Aged; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Retinopath | 1983 |
Management of newly diagnosed non-insulin-dependent diabetes mellitus in the primary care setting: effects of 2 years of gliclazide treatment--the Diadem Study.
Topics: Aged; Albuminuria; Cardiovascular Diseases; Cerebrovascular Disorders; Clinical Protocols; Cohort St | 1997 |
[A new therapeutic approach to diabetes. Long-term survey].
Topics: Adult; Aged; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus; Diabetic Retinopathy; Drug | 1977 |
Gliclazide in the treatment of diabetic retinopathy.
Topics: Clinical Trials as Topic; Diabetic Retinopathy; Female; Gliclazide; Humans; Male; Middle Aged; Retin | 1979 |
Diabetic retinopathy in non-insulin-dependent diabetes mellitus patients: the role of gliclazide.
Topics: Diabetes Mellitus, Type 2; Diabetic Retinopathy; Gliclazide; Humans | 1991 |
Long-term comparison of oral hypoglycemic agents in diabetic retinopathy. Gliclazide vs. other sulfonylureas.
Topics: Diabetes Mellitus, Type 2; Diabetic Retinopathy; Diet, Diabetic; Female; Gliclazide; Humans; Hypogly | 1988 |
7 other studies available for gliclazide and Diabetic Retinopathy
| Article | Year |
|---|---|
The Effect of CYP2C9 Genotype Variants in Type 2 Diabetes on the Pharmacological Effectiveness of Sulfonylureas, Diabetic Retinopathy, and Nephropathy.
Topics: Biomarkers; Blood Glucose; Cytochrome P-450 CYP2C9; Diabetes Mellitus, Type 2; Diabetic Nephropathie | 2020 |
Gliclazide attenuates the intracellular Ca2+ changes induced in vitro by ischemia in the retinal slices of rats with streptozotocin-induced diabetes.
Topics: Aniline Compounds; Animals; Calcium; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Gliclazi | 2005 |
Activation of nicotinamide adenine dinucleotide phosphate (reduced form) oxidase by advanced glycation end products links oxidative stress to altered retinal vascular endothelial growth factor expression.
Topics: Acetophenones; Animals; Blotting, Western; Cattle; Diabetic Retinopathy; Endothelial Cells; Enzyme A | 2006 |
Preventive and therapeutic effects of gliclazide on diabetic retinopathy: comparison with glibenclamide treatment.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Female; Gliclazide; Glyburide; Humans; | 1983 |
Gliclazide in the treatment of obese NIDDM patients.
Topics: Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Gliclazide; Human | 1994 |
Effective and selective prevention of retinal leukostasis in streptozotocin-induced diabetic rats using gliclazide.
Topics: Animals; Cell Adhesion; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Gliclazide; Hypoglyce | 2002 |
[The adhesiveness of platelets and the alteration of retinal capillaries. An experimental study in streptozotocin-induced diabetic rats (author's transl)].
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Gliclazide; Platelet Adhesiveness; R | 1979 |